Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Pimitespib||TAS-116|TAS116||HSP90 Inhibitor 35||Pimitespib (TAS-116) is a selective inhibitor of HSP90-alpha and HSP90-beta, which may lead to decreased tumor growth (PMID: 25416789, PMID: 31857719, PMID: 31536852, PMID: 30679388).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung non-small cell carcinoma||not applicable||Pimitespib||Phase I||Actionable||In a Phase I trial, TAS-116 treatment resulted in partial response in 2 patients with non-small cell lung carcinoma (J Clin Oncol 35, 2017 (suppl; abstr 2546)).||detail...|
|Unknown unknown||Advanced Solid Tumor||not applicable||Pimitespib||Phase I||Actionable||In a Phase I trial, TAS-116 demonstrated safety and resulted in a disease control rate of 27% (16/60; including stable disease for greater than or equal to 12 weeks (13) and partial responses (3)), in patients with advanced solid tumors, with partial responses in 2 patients with non-small cell lung cancer and 1 patient with gastrointestinal stromal tumor (PMID: 30679388; NCT02965885).||30679388|
|Unknown unknown||gastrointestinal stromal tumor||not applicable||Pimitespib||Phase II||Actionable||In a Phase II trial, treatment with Pimitespib (TAS-116) in patients with a gastrointestinal stromal tumor who failed previous therapy (n=40) resulted in a progression-free survival of 4.4 months, a median overall survival of 11.5 months, a 0% objective response rate, and a disease control rate of 85%, with 34 patients achieving stable disease, and one patient experienced a 37.2% decrease in tumor size after the analysis cut-off date (PMID: 31536852).||31536852|
|Unknown unknown||gastrointestinal stromal tumor||not applicable||Pimitespib||Phase I||Actionable||In a Phase I trial, TAS-116 treatment resulted in partial response in a patient with gastrointestinal stromal tumor (J Clin Oncol 35, 2017 (suppl; abstr 2546)).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02965885||Phase I||Pimitespib||A Study of TAS-116 in Patients With Solid Tumors||Completed|